BlossomHill Therapeutics, Inc.

Requisition # BH-2026-042

About the role

BlossomHill Therapeutics, Inc. is seeking a motivated professional to join our team in advancing innovative treatments for chronic diseases. This position will contribute to the development and execution of therapeutic strategies in a dynamic biotechnology environment.

About BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for chronic diseases with significant unmet medical needs. The company is publicly traded on the Nasdaq (XNAS) and headquartered in the United States.

Key Insider Transactions

• ORBIMED ADVISORS LLC: Purchased 625,000 shares at $16.00 per share on 10 August 2026 (total value: $10M).
• GORDON CARL L: Purchased 625,000 shares at $16.00 per share on 10 August 2026 (total value: $10M).
• Chen Bihua: Purchased 312,500 shares at $16.00 per share on 10 August 2026 (total value: $5M).
• Schmid John P.: Purchased 6,000 shares at $16.00 per share on 10 August 2026 (total value: $96,000).
• Keyes Jason A: Purchased 700 shares at $16.00 per share on 10 August 2026 (total value: $11,200).
• Liptak Vincent Paul:
  • Purchased 2,500 shares at $15.80 per share on 7 August 2026 (total value: $39,500).
  • Purchased 2,200 shares at $16.00 per share on 10 August 2026 (total value: $35,200).

Most recent insider filings were reported on 12 August 2026, with a total of 21 declarations. All transactions are subject to a 90-day holding period (canonical exit dates noted above).